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Abstract
Context—Endothelial function is abnormal in chronic obstructive pulmonary disease (COPD);
whether endothelial dysfunction causes COPD is unknown.
Objective—Test associations of endothelial biomarkers with FEV1 using instrumental variables.
Methods—Among 26 907 participants with spirometry, ICAM-1, P-selectin, E-selectin and
endothelin-1 were measured in subsets.
Results—ICAM-1 and P-selectin were inversely associated with FEV1 among European-
Americans (−29 mL and −34 mL per standard deviation of log-transformed biomarker, p<0.001),
as was endothelin-1 among African-Americans (−22 mL, p=0.008). Genetically-estimated
ICAM-1 and P-selectin were not significantly associated with FEV1. The instrumental variable for
endothelin-1 was non-informative.
Conclusion—Although ICAM-1, P-selectin and endothelin-1 were inversely associated with
FEV1, associations for ICAM-1 and P-selectin do not appear causal.
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Introduction
Chronic obstructive pulmonary disease (COPD), defined as an obstructive pattern of
spirometry that is not reversible with bronchodilators, is the fourth leading cause of death
worldwide (Decramer et al., 2012). The major risk factor for COPD in developed countries
is cigarette smoking; however, smoking is neither a necessary nor a sufficient cause of
COPD. Endothelial function is abnormal in severe COPD (Dinh-Xuan et al., 1991), but the
extent to which endothelial dysfunction contributes to COPD pathogenesis remains unclear
given the current, cross-sectional literature on the topic. Such cross-sectional studies cannot
traditionally define the direction of an association and may be subjected to bias and
confounding.
There are strong biological hypotheses to support a causal role for endothelial dysfunction in
COPD. Mechanisms by which abnormalities in endothelial cell function may lead to the
development or progression of COPD include adhesion molecule-mediated monocyte,
neutrophil, and T-cell adhesion and infiltration (Hogg et al., 2004); vaso- and
bronchoconstriction promoted by endothelin-1 (ET-1) (Redington et al., 1995; Yanagisawa
et al., 1988); vascular endothelial growth factor (VEGF)-dependent, ceramide-mediated
apoptosis of endothelial cells (Petrache et al., 2005); and micro-thrombosis in the pulmonary
vasculature (Voelkel & Cool, 2003).
Biomarkers for endothelial dysfunction include adhesion molecules and ET-1, which are
also appealing therapeutic targets in COPD given their extant pharmacologic inhibitors.
Cross-sectional associations between these biomarkers and lung function have been
demonstrated in several studies. The adhesion molecules, Intracellular Adhesion Molecule 1
(ICAM-1), P-selectin and E-selectin are elevated in COPD compared to controls and are
associated with lung function in the general population (Cella et al., 2001; Rusznak et al.,
2000; Thyagarajan et al., 2009; Walter et al., 2008). ET-1 is elevated in the bronchial
epithelial cells and airways of asthmatic and COPD patients (Spiropoulos et al., 2003;
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Trakada et al., 2000; Vittori et al., 1992), and plasma ET-1 is elevated in COPD
exacerbations (Roland et al., 2001). Nonetheless, prior studies have not clarified whether
elevated levels of these circulating biomarkers bear a causal relation to COPD development,
or if they simply reflect the cascading results of hypoxic, infectious and cigarette-related
endothelial damage.
Instrumental variable analysis may provide an approach to circumvent problems of reverse
causation and uncontrolled confounding in the non-experimental setting. Genotype can be
used to estimate biomarker levels, which serve as instrumental variables that may be
analyzed with respect to the disease of interest. Since genotype is fixed at conception and is
free of environmental or behavioral confounding, associations between genetically-
estimated biomarker levels and disease support a causal relationship (Ebrahim & Davey
Smith, 2008; Lawlor et al., 2008). This technique, also known as Mendelian Randomization,
has been used to demonstrate that low density lipoprotein (LDL) cholesterol and
lipoprotein(a), but not C-reactive protein or high-density lipoprotein, may be causally related
to cardiovascular disease (Elliott et al., 2009; Kamstrup et al., 2009; Linsel-Nitschke et al.,
2008; Voight et al., 2012). It has not been applied, to our knowledge, to ICAM-1, the
selectins or ET-1, with respect to lung function.
We therefore first tested for cross-sectional associations between soluble ICAM-1, P-
selectin, E-selectin, and ET-1 and lung function among 20 021 European-Americans and
6886 African-Americans from the National Institutes of Health/National Heart, Lung, and
Blood Institute (NIH/NHLBI) Candidate-gene Association Resource (CARe) (Musunuru et
al., 2010). We then tested whether the observed associations may be causal by examining
the association of genetically-estimated biomarker levels with lung function.
Methods
Study sample
We included the seven NIH/NHLBI cohorts in CARe that measured lung function:
Atherosclerosis Risk in Communities (ARIC) Study, offspring and generation three cohorts
from Framingham Heart Study (FHS), Cardiovascular Health Study (CHS), Jackson Heart
Study (JHS), Coronary Artery Risk Development in Young Adults (CARDIA), Multi-Ethnic
Study of Atherosclerosis (MESA) Lung Study and Cleveland Family Study (CFS). The
recruitment and designs of the cohorts have been previously described and are summarized
in the Online Supplement. The cohorts included in this analysis recruited unrelated
participants except for FHS and CFS, which included families. All cohorts enrolled
European- and African-American participants except for FHS and JHS, which enrolled only
European-Americans and African-Americans, respectively.
Exclusion criteria were lack of valid spirometric or genetic data, age less than 23 years, and
a restrictive pattern of spirometry, defined as forced vital capacity (FVC) less than the lower
limit of normal (Hankinson et al., 1999) with a forced expiratory volume in 1 s (FEV1)/FVC
ratio of greater than 0.70 (see Online Supplement). In addition, carriers of T-alleles at SNP
rs5491 were excluded from analyses of ICAM-1 as such participants demonstrate
factitiously low levels of ICAM-1 on the R&D Systems Assay used by the majority of
cohorts (see Online Supplement) (Bielinski et al., 2008).
Appropriate Institutional Review Boards approved study protocols and written informed
consent was obtained from all participants.
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Spirometry—Pre-bronchodilator spirometric measurements were performed by trained and
certified spirometry technicians using highly standardized methods and spirometry systems
in accordance with American Thoracic Society guidelines (see Online Supplement). Airflow
limitation was defined as FEV1/FVC ratio less than the lower limit of normal (Hankinson et
al., 1999).
Biomarkers—Fasting blood samples were drawn, processed and stored using standardized
procedures in central laboratories. Soluble biomarker concentrations were determined as
described in the Online Supplement. Biomarker measurements were performed at the same
visit as spirometry and were measured on the whole cohort or a random subset except as
noted in the Online Supplement.
Covariates—Age, gender and race were self-reported. Participants who reported smoking
fewer than 100 cigarettes in their lifetime were classified as never smokers, and those who
reported smoking during the last 30 d were classified as current smokers. Pack-years of
cigarette smoking were calculated as years smoked × cigarettes per day/20. Height and
weight were measured using standardized protocols with a stadiometer and balance scales.
Genotyping
The CARe consortium genotyping platform was the ITMAT-Broad-CARe (IBC) Illumina-
iSELECT array, a 50 000 gene-centric SNP genotyping array. The SNPs were selected to
densely tag approximately 2100 candidate genes primarily related to cardiovascular disease,
including the genes for adhesion molecules and ET-1. Additional details regarding
procedures and quality control are provided in the Online Supplement.
Statistical analysis
Our primary endpoint for this analysis was the FEV1, since previous studies have shown
associations between this measurement and adhesion molecules. The FEV1/FVC ratio
served as a secondary endpoint. Soluble biomarker concentrations were log-transformed to
obtain approximately normal distributions. Race-stratified Pearson correlations between log-
biomarker levels were computed.
Lung function was regressed on each log-transformed biomarker using generalized linear
models stratified by race and adjusted for sex, age, height, weight, cohort, site, smoking
status, pack-years and the first three genetic principal components. These latter terms were
generated using EIGENSTRAT (Harvard University, Boston, MA) (Price et al., 2006).
Generalized estimating equations were used to account for familial clustering (Zeger &
Liang, 1986). Covariates were specified a priori and were chosen based upon known
determinants of lung function (sex, age, smoking, principal components) as well as precision
variables (height, weight, cohort, site). Interactions with site and cohort were tested using
interaction terms.
To characterize gene-biomarker associations, each log-transformed biomarker was regressed
on its respective candidate SNPs within ICAM1, SELP, SELE or EDN1 using multiple linear
regression under an additive genetic model. The threshold for statistical significance was set
at a Bonferroni-corrected p<0.05. Significantly-associated SNPs were retained and their
association with lung function was examined in similar models to examine gene-lung
function associations.
Next, each log-transformed biomarker was regressed on the respective retained SNPs using
unadjusted linear regression to derive a prediction equation. This prediction equation was
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used to determine a genetically-estimated predicted value for each biomarker for each
participant based upon genotype at the retained SNPs. The proportion of variance in soluble
biomarker levels explained by the genetic prediction equations was computed (R2), as well
as the proportion of variance explained by the prediction equations plus the covariates
(adjusted R2).
Instrumental variable analysis proceeded as follows. The association of the genetically-
estimated biomarker values, or instrumental variables, with lung function was tested using
generalized linear models. The delta method of deriving approximate probability
distributions was used to compute standard errors that reflect the variance in the subject-
specific predicted values. All models were stratified by race and adjusted for the same
covariates.
The threshold for statistical significance for these analyses was set at p<0.05 since there was
only one primary outcome (FEV1) and all performed analyses are reported (Rothman, 1990).
Instrumental variable analyses were also repeated using all SNPs found to be significantly
associated with a given biomarker among the 50 000 gene-centric SNPs in CARe.
Cross-sectional and instrumental variable analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC). Additive genetic models were executed in PLINK version 1.07
(Harvard University, Boston, MA) (Purcell et al., 2007).
Results
Characteristics of the 20 021 European- and 6886 African-American participants included
from the seven cohorts are shown in Table 1. The mean age of the included participants was
54 years, 44% were men, 52% had smoked cigarettes with a median of 20 pack-years and
17% had airflow limitation.
In this sample, ICAM-1 was measured for 10 289 participants, P-selectin for 4243, E-
selectin for 418 and ET-1 for 2432. Median biomarker levels are shown in Table 1.
Compared to participants without biomarker measurements, participants with biomarker
measurements were slightly younger, and less likely to smoke or to have airflow limitation
(Online Supplementary Table 1).
ICAM-1 was correlated with P-selectin (r=0.15 and r=0.28 among European- and African-
Americans, respectively [both p<0.001]) and E-selectin (r=0.31 [p<0.001] and r=0.26
[p=0.005], respectively). In contrast, ET-1 levels were negatively correlated with P-selectin
(r=−0.38, p=0.04) and not correlated with ICAM-1 (p=0.76).
Endothelial biomarkers and lung function
Higher levels of ICAM-1 were significantly associated with a lower FEV1 among European-
Americans (Table 2). An association of similar magnitude was observed among African-
Americans, and the combined analysis showed that a one standard deviation (SD) increase
in ICAM-1 was associated with a 34 mL decrement in the FEV1. In European-Americans,
the relationship between ICAM-1 and the FEV1/FVC ratio was consistent with that for the
FEV1 but fell short of statistical significance. A similar pattern of association with lung
function was observed for P-selectin. In the small sample with E-selectin levels, there were
no significant, inverse relationships between the biomarker and lung function.
Higher levels of ET-1 were significantly associated with lower FEV1 among African-
Americans, with a one SD increase in ET-1 associated with a 22 mL decrement in FEV1.
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The association of ET-1 with FEV1/FVC ratio was in a consistent direction, but was not
statistically significant.
There were no significant interactions by cohort or site.
Genetically-estimated biomarker levels and lung function
Among European-Americans, the proportion of variance in biomarker levels explained by
the retained candidate SNPs (R2) was 1.3% for ICAM-1 and 5.9% for P-selectin. Among
African-Americans, the R2 was 1.0% for ICAM-1 and 1.6% for P-selectin (Supplementary
Table 2). No SNPs within SELE or EDN1 were significantly associated with E-selectin or
ET-1, respectively, and therefore instrumental variables were not created for these two
biomarkers.
There were no significant associations found between genetically-estimated levels of
ICAM-1 or P-selectin and the FEV1 among European- or African-Americans (Table 3).
Effect estimates were close to the null and 95% confidence intervals excluded clinically
meaningful differences. Similarly null relationships were observed for the FEV1/FVC ratio.
Findings were similar in sensitivity analyses among non-smokers, heavy smokers and
participants with airflow limitation (Online Supplementary Tables 6–8). No significant
associations were found when restricting to participants less than 55 years of age,
participants with at least one biomarker measurement, or, for ICAM-1, all participants
including T-allele carriers at rs5491.
Discussion
In this large, bi-racial study of seven pooled cohorts, soluble levels of ICAM-1 and P-
selectin were inversely associated with the FEV1 in a trend consistent with an obstructive
pattern of spirometry. However, there was no evidence to suggest a causal relationship of
these biomarkers to lung function given the negative findings for genetically-estimated
levels of ICAM-1 or P-selectin and lung function. We also demonstrated, for the first time in
a large sample, that serum ET-1 levels were inversely related to lung function, although we
were unable to genetically estimate ET-1 levels due to inadequate power.
These associational results are consistent with biologic and epidemiologic data supporting
alterations in adhesion molecules in COPD. ICAM-1, P-selectin and E-selectin are known to
recruit neutrophils, monocytes and T-cells, which are central to COPD histopathology and
pathogenesis (Hogg et al., 2004). Cell cultures from patients with COPD increase ICAM-1
gene expression and release more ICAM-1 versus cells from controls (Rusznak et al., 2000).
Studies of “bronchitics” and patients with COPD have found mixed evidence for increased
expression of ICAM-1, P- and E-selectin among the subset of patients with an obstructive
component to their disease (Cella et al., 2001; Di Stefano et al., 1994; Ferroni et al., 2000;
Noguera et al., 1998; Riise et al., 1994). Prior reports from the CARDIA and Framingham
cohorts have shown ICAM-1 and P-selectin to be inversely associated with the FEV1
(Thyagarajan et al., 2009; Walter et al., 2008), data from which were included in the current
study.
No prior large studies, to our knowledge, have demonstrated an association between serum
ET-1 and the FEV1. In one small case-control study, sputum ET-1 levels were shown to be
elevated in nine COPD patients at baseline, but not plasma levels (Chalmers et al., 1999). In
a sample of 67 COPD patients, plasma ET-1 levels were inversely associated with baseline
FEV1 and FVC, and during exacerbations, both sputum and plasma levels of ET-1 were
shown to increase (Roland et al., 2001). There is mixed evidence from small studies
regarding whether baseline peripheral plasma ET-1 levels are elevated in COPD and
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emphysema compared to controls, and whether elevations are limited to subjects with
pulmonary hypertension (Carratu et al., 2008; Celik & Karabiyikoglu, 1998; Yamakami et
al., 1997). ET-1 classically exerts potent intravascular effects such as vasoconstriction and
resultant pulmonary hypertension, up-regulation of inflammatory cytokines and leukocyte
accumulation, but also causes airway effects including mucous secretion, airway edema and
bronchial hyper-responsiveness (Helset et al., 1996; Redington et al., 1995; Roland et al.,
2001; Yanagisawa et al., 1988).
Although the magnitude of the biomarker-lung function associations shown in our analysis
was modest, this is expected in a general population sample. These results, however, are also
much less likely to be biased by factors that affect clinical cases versus controls (e.g.
medication and treatment effects, comorbidities, selection bias) and hence may provide
biological insights that are likely to be magnified in clinical populations, especially if the
biomarkers play a causal role. To investigate this possibility, we performed instrumental
variable analysis.
We examined the relationships of genetically-estimated levels of adhesion molecules with
lung function, since these associations are theoretically free of reverse causation, as well as
environmental or behavioral confounding (Ebrahim & Davey Smith, 2008). There was no
convincing evidence to suggest that genetically-determined variability in ICAM-1 or P-
selectin is causally related to lung function. In fact, with respect to the association between
genetically-estimated ICAM-1 and P-selection and the FEV1, effect estimates approached
zero, and narrow 95% confidence intervals effectively ruled out any clinically meaningful
relationships (i.e. all upper and lower limits were absolutely less than 200 mL). The negative
findings were consistent in the large, total sample, as well as in race-stratified and sensitivity
analyses.
We are not aware of any prior studies using this technique to examine whether these
biomarkers are causally associated with lung function. Two recent instrumental variable
analyses yielded non-significant results with respect to COPD and the inflammatory
biomarkers CRP (Dahl et al., 2011) and IL6 (van Durme et al., 2011). A recent study also
suggested that genetic variants associated with plasma E-selectin levels may be causally
associated with diabetes risk (Qi et al., 2010).
In addition to the use of novel techniques, this study’s strengths include a large pooled
sample from well-characterized population-based cohorts, a strong biological hypothesis,
and consistent methods for spirometry, biomarker assay and genotyping. Nonetheless, there
are a number of limitations. While pooling data from heterogeneous cohorts is inferior to
performing one extremely large study, pooling allowed an adequate sample size of
participants broadly recruited from the general US population who were phenotyped and
genotyped using highly standardized and often identical protocols. We furthermore found no
evidence for confounding or interaction by cohort. With regards to biomarker
measurements, this study analyzed soluble levels, whereas membrane-bound adhesion
molecules play a more direct role in neutrophil diapedesis and parenchymal infiltration
(DiStasi & Ley, 2009). However, soluble ICAM-1 and the selectins are correlated with their
membrane-bound expression and provide an index for endothelial activation (Fijnheer et al.,
1997; Pigott et al., 1992). ET-1 is also produced in large part by endothelium and secreted
into the bloodstream (Yanagisawa et al., 1988), where it exerts potent vasoconstrictive and
inflammatory effects.
The inherent limitations of instrumental variable analysis include the following underlying
assumptions (Glymour et al., 2012). There must be no unmeasured common determinants of
genotype and lung function, such as population heterogeneity, which we have addressed by
Oelsner et al. Page 7













race stratification and adjustment for principal components of ancestry. Valid instrumental
variables should only be associated with the outcome via the biomarker. To address this, we
only used SNPs within each biomarker’s respective candidate gene; however, we cannot
completely exclude the possibility of genetic pleiotropy given the current state of
knowledge. Weak instruments, which are only weakly correlated with the biomarker of
interest, may also introduce bias. While our genotype-biomarker associations had only
modest predictive power, probably due to the relative importance of non-genetic sources of
variation for these biomarkers, our instrument strengths for ICAM-1 and P-selectin were
similar to prior publications (Elliott et al., 2009; Kamstrup et al., 2009; Linsel-Nitschke et
al., 2008). Using additional SNPs outside of the candidate genes did not substantially
improve our instrument strength and introduced the potential problem of genetic
confounding via pleiotropic effects of the ABO blood group gene (ABO) on glycosylation
and transport of adhesion molecules. Since we were unable to generate reliable instrumental
variables for E-selectin or ET-1, we did not analyze these biomarkers in this fashion.
Another potential limitation was power, despite the large sample. The derivation of
instrumental variables relied upon the subsets with biomarker measurements, and the
number with E-selectin and ET-1 was too small to generate reliable estimates. The same was
broadly true for African-American subjects. For ICAM-1 and P-selectin, among European-
Americans, we maximized our power by using the genotype-biomarker associations
demonstrated in subsets to impute instrumental variables for the entire sample.
We believe that the uniformity of negative results in this large sample makes type II error
unlikely, and strongly suggests that genetically-determined variability in ICAM-1 and P-
selectin does not play a major causal role in low lung function. Of note, we did not rule out
the possibility that environmentally-determined variability in ICAM-1 and P-selectin could
still contribute to decrements in lung function, or that these biomarkers may mediate
environmental risk related to smoking and other risk factors.
Conclusions
Soluble ICAM-1 and P-selectin were consistently and inversely associated with lung
function; however, there was no evidence for an association between lung function and
genetically-estimated levels of ICAM-1 and P-selectin, and hence no support for a causal
relationship. Serum ET-1 was inversely associated with the FEV1 among African-
Americans, which is novel, biologically plausible, and potentially therapeutically evocative,
however inadequate power prevented the examination of causal inference for ET-1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2




















ICAM-1 N=8727 N=843 N=9570
FEV1 (mL) −29 (−43, −15) <0.001 −45 (−117, 26) 0.22 −34 (−50, −18) <0.001
FEV1/FVC (%) −0.20 (−0.42, 0.02) 0.07 0.15 (−1.00, 1.30) 0.80 −0.20 (−0.45, 0.04) 0.10
P-Selectin N=3359 N=884 N=4243
FEV1 (mL) −34 (−51, −18) <0.001 −13 (−41, 15) 0.36 −32 (−47, −18) <0.001
FEV1/FVC (%) −0.23 (−0.47, 0.01) 0.06 0.23 (−0.18, 0.63) 0.27 −0.15 (−0.37, 0.06) 0.16
E-Selectin N=295 N=123 N=418
FEV1 (mL) −3 (−53, 48) 0.99 51 (−16, 117) 0.13 16 (−24, 57) 0.42
FEV1/FVC (%) −0.22 (−1.03, 0.59) 0.59 1.62 (0.31, 2.92) 0.02 0.19 (−0.50, 0.87) 0.59
Endothelin-1 N=2432
FEV1 (mL) −22 (−38, −6) 0.008
FEV1/FVC (%) −0.22 (−0.54, 0.10) 0.18
ICAM-1 models were adjusted for age, sex, height in centimeters, weight in pounds, smoking status, pack-years, cohort, site and principal
components 1–3; race was also adjusted for in analyzing the total sample; clustering by family was accounted for by general estimating equations;
rs5491 T-allele carriers excluded.
P-selectin models were adjusted for age, sex, height in centimeters, weight in pounds, smoking status, pack-years, cohort, site and principal
components 1–3; race was also adjusted for in analyzing the total sample; clustering by family was accounted for among European-Americans and
the total sample.
E-selectin models were adjusted for age, sex, height in centimeters, weight in pounds, smoking status, pack-years, site and principal components 1–
3; race was also adjusted for in analyzing the total sample.
Endothelin-1 models were adjusted for age, sex, height in centimeters, weight in pounds, smoking status, pack-years, site and principal components
1–3.
SD=Standard Deviation, 95% CI=95% Confidence Interval, ICAM-1=Intercellular Adhesion Molecule 1, FEV1=forced expiratory volume in one
second, mL=milliliters, FEV1/FVC=ratio of forced expiratory volume in one second over forced vital capacity as a percent.
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Table 3
Instrumental variable analysis of the associations of genetically-estimated biomarker levels with lung function
using the retained candidate single nucleotide polymorphisms (SNPs).
European-Americans African-Americans Total
Mean difference






















Model 1 25 (−38, 89) 0.44 51 (−100, 201) 0.51 27 (−30, 85) 0.36
Model 2 −4 (−59, 52) 0.90 9 (−147, 166) 0.91 2 (−50, 54) 0.94
FEV1/FVC (%)
Model 1 0.18 (−0.8, 1.2) 0.73 −0.57 (−1.7, 0.6) 0.69 −0.054 (−0.9, 1.0) 0.91
Model 2 −0.18 (−1.0, 0.7) 0.68 −1.3 (−4.8, 2.2) 0.52 −0.32 (−1.1, 0.5) 0.37
P-Selectin
FEV1 (mL)
Model 1 2 (−27, 31) 0.89 39 (−69, 147) 0.48 2 (−24, 27) 0.91
Model 2 −7 (−32, 19) 0.61 20 (−77, 117) 0.69 −4 (−60, 53) 0.53
FEV1/FVC (%)
Model 1 −0.026 (−0.5, 0.4) 0.90 1.5 (−2.7, 5.6) 0.48 0.072 (−0.4, 0.5) 0.73
Model 2 −0.26 (−0.9, 0.4) 0.31 1.1 (−2.6, 4.7) 0.57 −0.14 (−0.5, 0.2) 0.49
None of the selected candidate SNPs for E-Selectin or Endothelin-1 was significantly associated with biomarker levels, hence instrumental
variables were not created.
Multivariate model 1 was adjusted for sex, age, height and cohort. Race was also adjusted for in the total sample. For ICAM-1, T-allele carriers at
rs5491 excluded.
Multivariate model 2 was adjusted for sex, age, height, cohort, smoking status, pack-years, weight, waist circumference and principal components.
Race was also adjusted for in the total sample. For ICAM-1, T-allele carriers at rs5491 excluded.
SD=Standard Deviation, 95% CI=95% Confidence Interval, ICAM-1=Intercellular Adhesion Molecule 1, FEV1=forced expiratory volume in one
second, mL=milliliters, FEV1/FVC=ratio of forced expiratory volume in one second over forced vital capacity as a percent.
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